

Could FASENRA® be an option for your patients?



Faith

Teacher | Age 32

Choose FASENRA® for patients like Faith

History:

- Diagnosed with severe asthma 3 years ago
- Experienced a second exacerbation in the last 12 months requiring OCS

Examination:

- Pre-bronchodilator FEV₁: 1.9 L (64%)
- Blood eosinophils: 300 cells/ μ L
- ACQ-6 score: 2.8

Current Treatments:

- High-dose ICS + LABA

Consult the [Product Monograph](#) for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling **1-800-668-6000**.

Reference: 1. FASENRA® Product Monograph, AstraZeneca Canada Inc.

FASENRA® (benralizumab injection) is indicated as an add-on maintenance treatment of adult patients with severe eosinophilic asthma.

Fictitious patient. May not be representative of all cases.
ACQ-6: Asthma Control Questionnaire, six-question version; FEV₁: forced expiratory volume in 1 second;
ICS: inhaled corticosteroid; LABA: long-acting beta₂-agonist; OCS: oral corticosteroid.